Muhammad Murtaza Hassan
Assistant Professor, Chemistry University of Virginia
Seminars
Monday 12th October 2026
Designing a Rational Bispecific ADC for New Therapeutic Opportunity Against Aggressive B-Cell Lymphoma
2:30 pm
- Contextualizing Double Hit Lymphoma (DHL) as a rare and highly aggressive B-cell lymphoma with rapid disease progression, treatment resistance, and poor patient survival outcomes
- Evaluating studies indicating CDK9 as a key driver of the aggressive and therapy-resistant behavior of DHL
- Developing a bispecific ADC to target CDK9 to selectively target DHL cells and mitigate off-tumor, on-target toxicity associated with past clinical failures
